LATE EFFECTS OF PIRARUBICIN IN THE TREATMENT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA: LONG-TERM FOLLOW-UP STUDY FROM THE CCLSG ALL 2004 STUDY IN JAPAN (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 01 - 038; Pres time: Sep 16, 2026; Location: Exhibition Area; "This trial was characterized by high cumulative doses of pirarubicin administered as doxorubicin equivalents; 99 mg/sqm for standard risk (SR), 255 mg/sqm for high risk (HR), 392 mg/sqm for high- high risk (HHR), and 379 (salvage-1) or 466 mg/sqm (salvage-2) for salvage arms in patients with a high end-of-consolidation minimal residual disease load. The analysis included 130, 45, and 18 patients with SR, HR, and HHR, respectively. Of these patients, eleven in SR received salvage-1, while one in HR and two in HHR underwent salvage-2. Cardiac biomarkers were mostly normal; only three cases (all SR) exceeded the BNP cutoff (>35 pg/mL)."
Clinical • Acute Lymphocytic Leukemia • Breast Cancer • Heart Failure • Hematological Malignancies • Leukemia • Metabolic Disorders • Pediatrics • Solid Tumor
|
|
Keisuke Okuno1; Yasuhiro Ikawa2; Yasuto Shimomura3; Toshinori Hori3; Masaru Imamura4; Kazumi Okamura5; Toshihiro Fujiki6; Takayuki Takachi7; Keiko Nomura8; Junko Yamanaka9; Satoru Hamada10; Takeshi Higa11; Yasutomo Funakoshi12; Michihiro Yano13; Masashi Hirayama14; Tsuyako Iwai15; Kenichiro Watanabe16; Hideki Sano17; Atsushi Ogawa18; Takashi Taga19; Chihaya Imai20
|